Pharmaceuticals, Biotechnology and Life Sciences
Evgen Pharma’s lead product, SFX-01, has been featured in a recently published paper, in the journal “Oxidative Medicine and Cellular Longevity”, describing Phase IIb trial in subarachnoid haemorrhage (“SAH”) at University Hospital Southampton.
The results of an evaluation of Evgen Pharma’s novel sulforaphane analogues suggest that some of the analogues merit further study as…
Evgen Pharma got the grant of the first European patent for its lead product, SFX-01.
Evgen Pharma said Tuesday that its lead product, SFX-01, will be tested against triple negative breast cancer (TNBC) in new preclinical research at the Manchester Cancer Research Centre, UK.
Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. APTrans is a Cheshire-based consortium of drug development companies.
Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, intends to join the AIM market of the London Stock Exchange by way of a Placing to raise approximately £5 million.